Entities / Entity
Daiichi Sankyo.
Japanese pharmaceutical company
- Reports this week
- 8
- Active events
- 2
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.Some support1 report1 development inside
-
The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.Some support8 reports
Earlier this month
-
Zevra Therapeutics and Daiichi Sankyo are involved in the competitive healthcare investment space, with Zevra developing products for serious medical conditions.Some support1 report
-
The Delhi High Court ordered a forensic audit and sought enforcement of an arbitration award against founder-linked entities.Some support3 reports1 development inside
-
Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.Some support2 reports
-
Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.Some support2 reports
One to three months ago
-
Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.Some support3 reports1 development inside
-
Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.Some support3 reports
-
Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.Some support2 reports
-
Daiichi Sankyo and Shuttle Pharmaceuticals are competing in the pharmaceutical market.Some support1 report
-
The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.Some support2 reports
-
Daiichi Sankyo and AstraZeneca are nearing a UK pricing deal for Enhertu, while Morgan Stanley and Bank of America issued recent rating updates.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
What's reaching Daiichi Sankyo
Recent events traced to Daiichi Sankyo, step by stepAround Daiichi Sankyo this week
News at the entities that move Daiichi Sankyo most-
AstraZeneca StructuralAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Daiichi Sankyo
-
Europe StructuralThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Daiichi Sankyo
-
Fortis OperationalTrump pledged to unleash American oil and gas production, specifically involving Matador Resources Company.Moves Daiichi Sankyo
-
Delhi Shared contextA high-level review on pollution was held in Delhi after the West Asia situation caused a bitumen supply disruption, affecting operational bodies like the DJB and Metro Corporation.Moves Daiichi Sankyo
-
Tokyo Shared contextEgypt is promoting tourism in Tokyo.Moves Daiichi Sankyo
-
Japan Shared contextSri Lanka joined the Sterling Assets Agreement and participated in the San Francisco Conference.Moves Daiichi Sankyo
Connections
The 13 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AstraZeneca Structural
The companies are engaged in a deep, ongoing partnership for the joint development and commercialization of advanced cancer treatments, including Enhertu and Datroway.
-
Michio Hayashi Structural
A holds the executive office of President for B, defining a formal leadership structure within the company.
-
Fortis Operational
The entities are engaged in an ongoing high-stakes legal dispute concerning shareholding and mandatory tender offer approvals.
-
AstraZeneca Operational
AstraZeneca and Daiichi Sankyo are actively engaged in both co-developing drugs and competing in the HER2-mutant NSCLC treatment market.
-
Innovent Biologics Structural
Exclusive agreement for the commercialization and supply of Vanflyta.
-
NTK Operational
The relationship is characterized by active market competition stemming from litigation regarding the acquisition of shares in the Fortis chain.
-
Fortis Healthcare Transactional
Daiichi Sankyo initiated legal enforcement proceedings over an arbitral award against entities linked to Fortis Healthcare.
-
Europe Structural
Daiichi Sankyo conducts clinical trials utilizing the regulatory and market infrastructure of various European Union countries.
Show all 13 connections
-
Fujitsu Operational
Both companies are major listed entities operating within the competitive landscape of the Japanese market.
-
Tokyo Shared context
Daiichi Sankyo is headquartered in Tokyo.
-
Delhi Shared context
Daiichi Sankyo is involved in an arbitration case held within the jurisdiction of Delhi.
-
Shivinder Mohan Singh Transactional
Shivinder Mohan Singh is involved in arbitration proceedings regarding Daiichi Sankyo.
-
Japan Shared context
Daiichi Sankyo is a global company that is based in Japan.
History
Events by the month they beganSeptember 2026
5 events- A dispute over mandatory tender offer approvals has arisen, leading to NCLT approval for the amalgamation of a subsidiary involving several companies.
- The Supreme Court disposed of the petition concerning the legal dispute between Fortis Healthcare and Daiichi Sankyo.
- Zevra Therapeutics and Daiichi Sankyo are involved in the competitive healthcare investment space, with Zevra developing products for serious medical conditions.
- Daiichi Sankyo and AstraZeneca partnered on the development of the Enhertu drug, which was tested in Etcamah trials combined with Ibrance as a UK drugmaker.
- Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.
August 2026
3 events- The Delhi High Court ordered a forensic audit and sought enforcement of an arbitration award against founder-linked entities.
- Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.
- Daiichi Sankyo and Innovent Biologics entered an exclusive agreement for the commercialization of the drug Vanflyta, with Michio Hayashi serving as China President of Daiichi Sankyo.
July 2026
3 events- Daiichi Sankyo and Shuttle Pharmaceuticals are competing in the pharmaceutical market.
- The European Medicines Agency and European Commission are jointly developing Enhertu for market approval and seeking authorization in the EU.
- Daiichi Sankyo and AstraZeneca are nearing a UK pricing deal for Enhertu, while Morgan Stanley and Bank of America issued recent rating updates.
Show 1 earlier month
June 2026
4 events- Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.
- The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.
- Daiichi Sankyo is headquartered in Tokyo, Japan.
- Daiichi Sankyo is conducting clinical trials across various EU countries.